Condition: Chronic Kidney Disease (Stages 4 and 5) · Kidney Disease · Type 2 Diabetes · Sponsor: Well Cell Global
The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
This description comes directly from the study's public registry record.
Richard Marchase, PhD · 205-612-4763 · rmarchase@gmail.com
Samantha Villaverde · 904-806-8280 · samantha@wellcellglobal.com
Always discuss trial participation with your own doctor first.
| Arizona Kidney Disease and Hypertension Center | Phoenix, Arizona, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07187479